Rating Change
RBC Capital reiterated its Outperform rating on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on October 30, 2026.
reiterateNASDAQ:LGND
RBC Capital Reiterates Outperform Rating on Ligand Pharmaceuticals Incorporated (LGND)
RBC Capital reiterated its Outperform rating on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on October 30, 2026.
At publication ·
What changed
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) · reiterate
- Firm
- RBC Capital
- Rating
- Outperform to Outperform
- Price at event
- $322.75
- Market capitalization
- $3.6B
At a glance
Key takeaways
- RBC Capital reiterated an Outperform rating on Ligand Pharmaceuticals (LGND) on October 30, 2026.
Market Context
Ligand Pharmaceuticals Incorporated operates in the Healthcare sector. The stock currently trades at $322.75 with a market capitalization of $3.6B. The stock has gained 74.9% over the past 52 weeks.
Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ligand Pharmaceuticals Incorporated.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ligand Pharmaceuticals Incorporated
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | N/A |
| Sep 25, 2026 | Barclays | Overweight | N/A |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 23, 2026 | Citigroup | Buy | N/A |
| Aug 14, 2026 | Leerink Partners | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View LGND Stock Page
Frequently Asked Questions
What does the Outperform rating mean for LGND?
A rating of Outperform from RBC Capital reflects the analyst's outlook on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LGND forecast page.